China breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 9.7% during the forecast period. The major factors that drive the market include the high prevalence of breast cancer, awareness programs by government and private organizations. According to the WHO, around 3,67,900 new cases were estimated in 2019 and more than 97,972 mortalities due to breast cancer. The breast cancer awareness programs for breast cancer in China run by the collaboration of private and government organizations. In 2016, the Roche partnered with China Cancer Rehabilitation Society to launch the awareness campaign called ‘Run for Her’. This Breast Cancer Public Awareness Project has generated more than 400 media reports and reached an audience of over 297 million readers. The movement delivered effectively the message that women should receive screening for breast cancer on a regular basis, and that early diagnosis and standardized treatment can improve both the disease outcome and quality of life.

Request a Free Sample of our China Breast Cancer Therapeutics Market: https://www.omrglobal.com/request-sample/china-breast-cancer-therapeutics-market

China breast cancer therapeutics market is segmented on the basis of therapy. The therapy segment is further classified into chemotherapy, hormone therapy, targeted therapy, radiation therapy and others (surgery). Among all therapies, chemotherapy market held the largest market share in the China breast cancer therapeutics market. Chemotherapy is most used when cancer in the lymph nodes and irrespective of tumor size or menopausal status. Along with that it is used for the treatment of breast cancer in premenopausal women and referred for those women who diagnosed with early stage breast cancer for hormone receptor negative and HER2 positive cancer. The types of chemotherapy include adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy is used to destroy cancer cells that have been spread and not seen by the imaging tests. This method helps in reducing the cancer cells that form a new tumor in the other place of the body. Adjuvant chemotherapy reduces the risk of breast cancer coming back. Neoadjuvant chemotherapy can be used to reduce the size of the tumor, so it can be removed with less widespread surgery.

A full Report of China Breast Cancer Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/china-breast-cancer-therapeutics-market

China Breast Cancer Therapeutics Market Segmentation

By Therapy

• Chemotherapy
• Hormone Therapy
• Targeted Therapy
• Radiation Therapy
• Others (Surgery)

Company Profiles

• AbbVie Inc.
• AstraZeneca PLC
• Eisai Co., Ltd
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis International AG
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.


For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-breast-cancer-therapeutics-market

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404